Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Sanofi SA ( (SNY) ), Sanofi ( (DE:SNW) ), Sanofi ( (SNYNF)) announced an update on their ongoing clinical study.

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

The study began on April 11, 2021, and was last updated on August 4, 2025. However, it has been terminated, which could impact the timeline for any potential market release of SAR444881.

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division. As the company said it was going to ...

French drug maker Sanofi dismissed Chief Executive Christopher Viehbacher less than 24 hours after the German-Canadian executive played down speculation over his departure.

Sanofi formed a deal to develop 15 experimental oncology and immunology drugs with Exscientia Plc with possible total payouts of as much as $5.2 billion, allying with a company that uses ...